3 results
Approved WMOCompleted
To estimate the bleeding risk with rivaroxaban, compared with ASA, in addition to a singleantiplatelet agent (clopidogrel or ticagrelor), in subjects with a recent ACS .
Approved WMORecruiting
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics and activity of ACP-196 in treating subjects with Waldenström disease.
Approved WMORecruiting
The purpose of this study is to evaluate the efficacy, activity, safety, pharmacodynamics and pharmacokinetics of ACP-196 in treating subjects with Mantle Cell Lymphoma (MCL)